American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Moderna cuts 2025 revenue to $2.2B after UK booster delay

by admin August 2, 2025
August 2, 2025
Moderna cuts 2025 revenue to $2.2B after UK booster delay

Moderna has lowered the high end of its 2025 revenue forecast, citing a delay in Covid vaccine shipments to the UK. The company now expects between $1.5 billion and $2.2 billion in revenue, down $300 million at the top of its earlier range.

The adjustment comes as Moderna continues to face dwindling Covid vaccine demand, while also moving forward with cost-cutting efforts, including a 10% workforce reduction.

Despite this, Moderna reported second-quarter revenue and earnings results that beat Wall Street expectations, with losses coming in smaller than anticipated.

Revenue guidance lowered as UK shipment pushed to 2026

On Friday, Moderna confirmed that instead of delivering spring Covid boosters to the UK at the end of 2025, the doses will now be shipped in the first quarter of 2026.

The company stated that the overall contract value with the UK government remains unchanged, but the timing of the delivery has shifted to align with the UK’s fiscal year-end.

As a result, the company reduced its annual revenue outlook by $300 million. Full-year guidance now sits between $1.5 billion and $2.2 billion, as compared with its earlier projection of up to $2.5 billion.

Shares of Moderna fell more than 6% in premarket trading on Friday following the announcement.

Second-quarter sales fall 41% year over year

For the second quarter, Moderna reported $142 million in revenue, which was higher than the $113 million analysts expected, according to data from LSEG.

However, sales were still down 41% compared with the same period last year, reflecting the ongoing decline in Covid vaccine demand.

The vast majority of the second-quarter revenue—$114 million—came from Moderna’s Covid shot. This exceeded analyst forecasts of $89 million, based on StreetAccount estimates.

The company’s respiratory syncytial virus (RSV) vaccine, meanwhile, posted negligible sales, far below the $5.9 million expected.

Net loss narrows as operating expenses reduced by 27%

Moderna posted a net loss of $825 million, or $2.13 per share, for the quarter. This compares with a net loss of $1.3 billion, or $3.33 per share, in the year-ago period.

Analysts had expected a larger quarterly loss of $2.97 per share, meaning Moderna’s results were better than anticipated.

The company attributed this outperformance in part to cost controls. Operating expenses dropped 27% year on year, from $1.6 billion to $1.1 billion.

Executives emphasised that expense management has been critical to supporting Moderna’s financials as Covid vaccine sales continue to decline.

Workforce reduction and cost management strategy

The updated revenue outlook came a day after Moderna announced plans to cut its workforce by 10%.

This move adds to a series of cost-cutting measures the company has implemented in response to weaker Covid-related sales.

The workforce reduction and expense cuts are aimed at helping Moderna sustain investment in new products while managing reduced revenue streams.

While the company’s Covid shot remains the largest contributor to revenue, Moderna continues to focus on broadening its pipeline, including vaccines targeting flu and RSV.

However, with negligible RSV sales in the second quarter, the company remains reliant on Covid boosters for the majority of its income.

The post Moderna cuts 2025 revenue to $2.2B after UK booster delay appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Brazil antitrust watchdog probes Microsoft after Opera complaint over edge browser practices
next post
US stock plunge as jobs data disappoints and tariff tensions rise

Related Posts

Federal Reserve holds interest rates steady as consumer...

February 1, 2024

TSMC Q3 earnings beat forecast with AI chip...

October 17, 2024

Who are Broadcom’s secret hyperscale AI chip clients?

December 14, 2024

Texas AG wins $1.4B settlement from Facebook-parent Meta...

August 1, 2024

Romance scams surge as fraudsters exploit love and...

February 14, 2025

Qualcomm approached Intel for a takeover, WSJ reports

September 21, 2024

Asia-Pacific stocks slide as Trump tariffs, Bank of...

February 25, 2025

Indian shares rally as Nifty and Sensex rebound...

November 2, 2024

After Epstein ‘bomb’ & Trump’s wrath, Elon Musk...

June 11, 2025

Will Trump’s tariff plans impact global steel trade?

February 10, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Saudi Arabia poised to raise September crude prices to five-month highs

      July 28, 2025
    • From $824 to over $1,300: how soaring rents are consuming American paychecks

      July 27, 2025
    • India-UK sign historic free trade deal: here’s all you need to know

      July 24, 2025
    • Talen Energy surges 25% to ATH after strategic natural gas power plant acquisition

      July 20, 2025
    • US visa bans on Brazilian judges spark diplomatic rift, cloud economic ties

      July 20, 2025

    Categories

    • Business (3,550)
    • Investing (2,686)
    • Latest News (2,024)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved